Duchenne Muscular Dystrophy

Latest News

Despite the AI-ECG model’s potential, the authors cautioned it must be evaluated in a structured clinical framework to ensure that it improves established monitoring methods rather than replaces them. | Image credit: Yan - stock.adobe.com
AI-Based Electrocardiogram Interpretation Detects LVSD in Muscular Dystrophy

June 30th 2025

Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction (LVSD) in patients with muscular dystrophy, a recent study found.

An analysis of outcomes from part 2 of the EMBARK trial included 14 patients who had received a placebo in part 1 of the study and were aged 8 to 9 years at crossover. | Image Credit: RFBSIP - stock.adobe.com
DMD Gene Therapy Shows Clinical Benefits in 8- and 9-Year-Old Patients

June 13th 2025

Based on western blot testing, patients who received gene therapy at 2 years old showed a mean dystrophin expression of 93.87% of normal. | Image Credit: Treecha - stock.adobe.com
DMD Gene Therapy Shows Efficacy, Safety in Patients Treated at 2 Years Old

May 23rd 2025

While patients should be closely monitored in the first 90 days post-treatment, delandistrogene moxeparvovec showed a manageable, consistent safety profile in a broad population of patients. | Image Credit: Hypnosis - stock.adobe.com
Delandistrogene Moxeparvovec Shows Long-Term Safety, Tolerability in Pooled Trial Data

May 16th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo